Most Recent
German biotech Fresenius Kabi has struck back at Samsung Bioepis's latest attack on the validity of its patents for a liquid formulation of top selling immunosuppressant drug Humira, accusing the Korean company of causing its sales to flag by infringing the patent.
Johnson & Johnson Medical and unit Ethicon have agreed to pay $300 million to settle two class actions brought by Shine Lawyers on behalf of Australian women implanted with pelvic mesh and tape devices.
Apple has been sued by a microneedling pen company that alleges it suffered loss when the tech giant removing its app from the App Store based on bogus claims of trade mark infringement.
Two alleged victims of a former Sydney doctor who pretended to be a plastic surgeon and performed breast augmentation surgeries that left them injured cannot make claims against Avant Insurance, an appeals court has ruled.
Pharmaceutical ingredient producer Alkaloids of Australia is facing a maximum $30 million penalty but has argued it should pay less than $1 million after pleading guilty to cartel conduct over the supply of a key chemical found in generic stomach cramp drugs.
Two law firms that filed competing class actions against regenerative medicine company Mesoblast for allegedly misleading shareholders about its Remestemcel-L treatment for COVID-19 complications have agreed to join forces and sidestep a beauty parade.
Former prime minister Scott Morrison has defended his decision to appoint himself as shadow minister of significant government portfolios during the COVID-19 pandemic, saying the times were extraordinary and the actions were taken as an emergency safeguard.
Ambulance Victoria is being sued by a former executive who claims she was not treated the same as her male colleagues and was subject to “disrespectful, undermining” conduct from senior colleagues.
Samsung Bioepis Australia has sued fellow biotechnology company Fresenius Kabi over a biosimilar of top selling immunosuppressant drug Humira, saying the invention ‘does not achieve the promise’ of a better formulation using fewer ingredients.
Bristol-Myers Squibb unit Celgene and two generic drug makers have withdrawn an application for ACCC approval of a patent settlement that would have allowed for an early launch of a generic version of blockbuster cancer drug Revlimid.